Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels
Expected to enroll 415 participants; interim results expected in Q3 2021
In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants
PARIS and LEXINGTON, MASS. - March 12, 2021 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. The Companies expect interim results from this trial in the third quarter of 2021.
(2)
ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
Yvonne Lungershausen, CEO, Avance Clinical said: As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results. Atossa Therapeutics have tapped the full scope of our CRO services including ClinicReady, our scientific and medical affairs specialist team. Australian clinical trials are recognized globally for their speed and accuracy and the fact that the clinical data
Mom accused of child abuse of toddler who had 12 medical procedures in Fort Worth yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Date Time
Qantas trials commonpass digital health pass on repatriation flights
Qantas has this week run its first customer trial of the CommonPass digital health app on its international repatriation flight from Frankfurt to Darwin.
This follows a successful trial with crew last month and comes as the national carrier prepares to support the resumption of COVID-safe international travel from late October.
The CommonPass smartphone app offers a convenient and secure method for verifying COVID test results and vaccination information to border or health officials and airline staff.
The app connects customers to certified testing labs so that results can be uploaded to the platform and customers can show they have proof of a negative COVID test result before their flight, which is a requirement on all repatriation flights Qantas is operating on behalf of the Australian Government.
Program For Free Medicare Insurance Sales Summit In Chicago Posted From:
The program for the National Medicare Insurance Sales Summit has been posted by the American Association for Medicare Supplement Insurance (AAMSI). This is a completely free day for agents who sell Medicare insurance solutions featuring some of the nation s top sales pros and industry leaders, announced Jesse Slome, AAMSI s director and organizer of the industry conference.
The free day event takes place on Wednesday, September 8, 2021 immediately preceding the National Medicare Supplement Insurance industry summit. The event will be held at the Schaumburg, IL Convention Center located a few miles from O Hare International Airport.